Substitute for form 1449A/PTO	CO TE IF KNOWN		
INFORMATION DISCLOSURE	Application Number	10/517,295	
STATEMENT BY APPLICANT	Filing Date	December 7, 2004	
STA LEMENT BY APPLICANT	First Named Inventor	Steven S. Carroll, et al.	
MAR 0 9 7005 5 (use appearly sheets as necessary)	Group Art Unit	1623	
A	Examiner Name		
Sheet Plate 1 of 3	Attorney Docket Number	21122YP	

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
110	1	6,777,395	BZ	Bhat et al.	08/17/2004
5	2	6,812,219	BI	LaColla et al.	11/02/2004
	3	US 2003/0060400	A1	LaColla et al.	03/27/2003
	4	US 2003/0050229	AI	Sommadossi et al.	03/13/2003
5	5	US 2004/0097461	121	Sommadossi et al.	05/20/2004
	6	US 2004/0072788	181	Bhat et al.	04/15/2004
7	7	US 2004/0147464	181	Roberts et al.	07/29/2004
Re	8	US 2004/0063658	A	Roberts et al.	04/01/2004
/			7,		
7					
7.					

	FOREIGN PATENT DOCUMENTS							
Exami Initials		Cite No.	Foreign Patent Document Office Number		t Kind Code (if known)	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY
AL	d	9	PCT	WO02/057425	Ar	Merck & Co., Inc.	<u> </u>	07/25/2002
		10	PCT	WO02/32920	82	Pharmasset Limited	d	04/25/2002
	-	11	PCT	WO03/093290	82	Genelabs Technolo	ogies, Inc.	11/13/2003
		12	PCT	WO02/057287	42	AL Merck & Co., Inc.		07/25/2002
		13	PCT	WO01/92282	AZ	AV Novirio Pharmaceuticals Limited		d 12/06/2001
7		14	PCT	WO01/90121	AZ	Novirio Pharmaceuticals Limited		d 11/29/2001
)	15	PCT	WO03/051899	A1	Ribapharm Inc.		06/26/2003
		16	PCT	WO03/062255	A2	Ribapharm Inc.		07/31/2003
ن	Z	17	PCT	WO03/062256	AI	Ribapharm Inc.		07/31/2003
Me		18	PCT	WO2004/065398	A2	Ribapharm Inc.		08/05/2004
Exa Sign	min atu	er re	L.	E. Crane	M. lea	m C	Date Considered	09/24/2006

*Examiner: Initial if reference considered, whether or not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449APTO		E IF KNOWN
INFORMATION DISCLOSURE	Application Number	10/517,295
6 STATEMENT BY APPLICANT	Filing Date	December 7, 2004
%'.	First Named Inventor	Steven S. Carroll et al.
MAR 0 9 2005 = (use of nany sheets as necessary)	Group Art Unit	1623
Y2. 37	Examiner Name	
Sheet 2 of 3	Attorney Docket Number	21122YP

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
				· · · · · · · · · · · · · · · · · · ·		
				1		

			FORE	IGN PATENT	T DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Patent Docume Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
Wel	19	PCT	WO2004/028481	A2	Genelabs Technologies, Inc.	04/08/2004
7	20	PCT	WO2004/002999	A2	Idenix (Cayman) Limited	01/08/2004
	21	PCT	WO2004/002422	A2	Idenix (Cayman) Limited	01/08/2004
We	22	PCT	WO2004/046331	82	Idenix (Cayman) Limited	06/03/2004
7						
Examin Signatu		L	. E. Crane	11/5/	Date Considered	09/24/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		1			ie if known
IN	LITUTE for form 1449B/PTO	DIS	CLOSURE	Application Number	10/517,295
(P)	ATEMENT BY		DI IOANIT	Filing Date	December 7, 2004
78	U' 1	Aľ	PLICANI	First Named Inventor	Steven S. Carroll, et al.
MAR 0	g was z			Group Art Unit	1623
Brew.	(use a many sheets	as r	necessary)	Examiner Name	
Sheet	3	of	3	Attorney Docket Number	21122YP

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
M	23	Anne B. Eldrup et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication", J. Med. Chem., Vol. 47, pp. 5284-5297 (2004)
	24	Anne B. Eldrup et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase", J. Med. Chem., Vol. 47, pp. 2283-2295 (2004)
	25	David B. Olsen et al., "A 7-Deaza-Adenosine Analog is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties", Antimicrobial Agents and Chemotherapy, Vol. 48, No. 10, pp. 3944-3953 (2004)
	26	Per Hoffmann et. al., "Recent Patents on Experimental Therapy for Hepatitis C Virus Infection", Expert Opin. Ther. Patents, Vol. 13(11), pp. 1707-1723, (2003)
Re	27	Volker Brass et al., "Recent Developments in Target Identification against Hepatitis C Virus", Expert Opin. Ther. Targets, Vol. 8(4), pp. 295-307, (2004)

Examiner Signature L. E. Cræne Me Cau Date Considered 09/24/2006

*Examiner: Initial if reference considered, whether print citation is in cw ormance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.